结直肠癌术后患者气虚证的兼夹特点及其影响因素的研究(4)
[12]McLeod HL，Sargent DJ，Marsh S，et al.Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer：results from North American Gastrointestinal Intergroup Trial N9741[J].J Clin Oncol，2010，28(20)：3227-3233.
[13]Ritchie KJ，Walsh S，Sansom OJ，et al.Markedly enhanced colon tumorigenesis in Apc(Min)mice lacking glutathione S-transferase Pi[J].Proc Natl Acad Sci U S A，2009，106(49)：20859-20864.
[14]Cong N，Liu L，Xie Y，et al.Association between glutathione S-Transferase T1，M1，and P1 genotypes and the risk of colorectal cancer[J].Journal of korean medical science，2014，29(11)：1488-1492.
[15]Ali-Osman F，Akande O，Antoun G，et al.Molecular cloning，characterization，and expression in escherichia coli of full-length cDNAs of three human glutathione S-transferase P1 gene variants.Evidence for differential catalytic activity of the encoded proteins[J].J Biol Chem，1997，272(15)：10004-10012.
[16]沈冬亞，谢海棠，陈尧，等.MTHFR，GSTP1，ERCC1基因多态性与结直肠癌FOLFOX化疗方案疗效相性研究[J].中国临床药理学与治疗学，2015，20(1)：75-80.
[17]Shen X，Wang J，Yan X，et al.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers：a systematic review and meta-analysis[J].2016，77(6)：1285-1302.
[18]Kensuke K，Keiichiro I，Norimichi O，et al.Polymorphisms of GSTP1，ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients[J].Oncol Lett，2013，6(3)：648-654.
[19]Avan A，Postma TJ，Ceresa C，et al.Platinum-Induced Neurotoxicity and Preventive Strategies：Past，Present，and Future[J].Oncologist，2015，20(4)：411-432.
[20]Lamas M J，Duran G，Balboa E，et al.Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer[J].Pharmacogenomics，2017，12(12)：433-442., http://www.100md.com(廖凌虹 魏丞 崔欢 王俊杰 吴同玉)
[13]Ritchie KJ，Walsh S，Sansom OJ，et al.Markedly enhanced colon tumorigenesis in Apc(Min)mice lacking glutathione S-transferase Pi[J].Proc Natl Acad Sci U S A，2009，106(49)：20859-20864.
[14]Cong N，Liu L，Xie Y，et al.Association between glutathione S-Transferase T1，M1，and P1 genotypes and the risk of colorectal cancer[J].Journal of korean medical science，2014，29(11)：1488-1492.
[15]Ali-Osman F，Akande O，Antoun G，et al.Molecular cloning，characterization，and expression in escherichia coli of full-length cDNAs of three human glutathione S-transferase P1 gene variants.Evidence for differential catalytic activity of the encoded proteins[J].J Biol Chem，1997，272(15)：10004-10012.
[16]沈冬亞，谢海棠，陈尧，等.MTHFR，GSTP1，ERCC1基因多态性与结直肠癌FOLFOX化疗方案疗效相性研究[J].中国临床药理学与治疗学，2015，20(1)：75-80.
[17]Shen X，Wang J，Yan X，et al.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers：a systematic review and meta-analysis[J].2016，77(6)：1285-1302.
[18]Kensuke K，Keiichiro I，Norimichi O，et al.Polymorphisms of GSTP1，ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients[J].Oncol Lett，2013，6(3)：648-654.
[19]Avan A，Postma TJ，Ceresa C，et al.Platinum-Induced Neurotoxicity and Preventive Strategies：Past，Present，and Future[J].Oncologist，2015，20(4)：411-432.
[20]Lamas M J，Duran G，Balboa E，et al.Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer[J].Pharmacogenomics，2017，12(12)：433-442., http://www.100md.com(廖凌虹 魏丞 崔欢 王俊杰 吴同玉)